|
Market Cap (5-Jun) $61,568,592 (1,444th) |
Close (30-Jun) $0.076 |
Volume (30-Jun) 120,981 |
Shortsold (26-May) 11,577 (0.00%) (629th) |
|
52w High $0.425 |
52w Low $0.056 |
P/E - |
EPS -0.02 |
ATX released this announcement to the ASX on 30 May 2023, 17:12. The announcement is not marked as price sensitive, and is 16 page(s) in length and 418.65kb in size.
You can view all announcements from ATX and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATX was 0.003% short sold according to ASIC data. It was ranked the 634th most shorted stock on the ASX. It is now ranked as the 629th most shorted stock on the ASX with 0.002% of total shares short sold as of the latest reported data (26 May 2026).
| Other Recent Announcements from ATX | |
|---|---|
| AMP945 International Nonproprietary Name Narmafotinib | 21 June 2023, 8:34 |
| Amplia AGM to be held Thursday 24 August 2023 | 19 June 2023, 17:34 |
| Key to Corporate Governance Disclosures | 31 May 2023, 8:14 |
| 2023 Corporate Governance Statement | 30 May 2023, 17:12 |
| Annual Report to Shareholders | 30 May 2023, 17:11 |
| AMP945 and FOLFIRINOX active in model of Pancreatic Cancer | 29 May 2023, 8:42 |
| Grant to collaborate with CSIRO Supplementary Announcement | 23 May 2023, 11:22 |
You must be logged in to post a reply.
Amplia Therapeutics 